Invesco Ltd. Purchases 24,303 Shares of Xencor, Inc. (NASDAQ:XNCR)

Invesco Ltd., a global investment management firm, has announced that it has purchased 24,303 shares of Xencor, Inc. NASDAQXNCR in the third quarter. This represents an increase of 4.6% in the company's stake in Xencor's stock. After the acquisition, Invesco Ltd. now owns a total of 555,809 shares of Xencor's stock.

Xencor, Inc. is a biopharmaceutical company that specializes in developing and commercializing novel therapies for the treatment of autoimmune diseases. The company has a pipeline of clinical-stage programs targeting multiple autoimmune indications, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

Invesco Ltd. is a leading global investment management firm that provides a wide range of investment products and services to individual and institutional investors. The company operates in more than 40 countries and has assets under management of over $1.2 trillion.

The acquisition of additional shares in Xencor's stock by Invesco Ltd. is a positive sign for the biopharmaceutical company, as it indicates that the investment firm believes in the potential of Xencor's pipeline and its ability to generate revenue from its therapies.